Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c512f7cf87a06b391f16bebb592ada8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-344 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3531 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 |
filingDate |
2016-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22c67a8de56aeceedbbc425533ed7349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_116b3291fa2539c7035b8842d04af236 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99818e777ef07bf23a02b53255726e1a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbed634eccb1396376a678dc466aa19a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f6e45e7bfd950a2ac649936dab80c19 |
publicationDate |
2018-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20180005754-A |
titleOfInvention |
MIR-155 inhibitor for skin T cell lymphoma (CTCL) treatment |
abstract |
The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The present invention also provides a method of treating cancer, such as a subject T cell lymphoma, by administering an oligonucleotide inhibitor of miR-155 to the subject. The present invention also provides a method of reducing or inhibiting proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155. |
priorityDate |
2015-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |